Strong Q1 prompts an improved guidance
05/05/21 -"2021 started on a high as Novo reported robust growth, despite ‘tough comps’, i.e. forward buying-driven Q1 20. Moreover, as management expects this momentum to be maintained, the 2021 outlook has ..."
Pages
75
Language
English
Published on
05/05/21
You may also be interested by these reports :
03/02/26
Roche’s shares have recovered c.34% in the last three months and are now close to the highs witnessed in April 2022, as investors eventually recover ...
29/01/26
The 2025 performance delivered on the management’s guidance, backed by a strong showing from the cornerstone immunology medicine Dupixent, newly ...
29/01/26
Roche finished the year on a strong note, backed by healthy performances across key focus areas. Even the 2026 guidance was encouraging. The ...
28/01/26
Lonza’s full-year 2025 CDMO performance surpassed management’s guidance. Top-line growth was driven by strong double-digit increases in Integrated ...